The Immune Oncology Research Institute has signed a cooperation agreement with Agenus and received a grant in order to enhance research cooperation. The purpose of this memorandum is to carry out joint research and educational activities in the field of cancer.
Agenus is a clinical-stage biopharmaceutical company that discovers, manufactures, and develops immunotherapies for cancer. Their portfolio consists of bio-engineered therapies designed to activate the body’s own defenses in order to fight cancer. These therapies are optimized through an integrated, proprietary active learning platform designed to deliver better drugs, optimized combinations, and predictive biomarkers to address critical unmet needs in cancer.
This is a great initiative to learn and grow with optimum partnerships.
About IMMONC
Immune Oncology Research Institute (IMMONC) is dedicated to advancing research aimed at preventing, treating, and ultimately curing cancer while making these innovations accessible to those who need them. If you're interested in joining our team, please feel free to contact us at [email protected] or at +374-41 310-048.